Akaza Research Releases OpenClinica 3.0 Electronic Data Capture Software
Waltham, MA
Akaza Research announced the release of OpenClinica 3.0, the newest version of the open source electronic data capture (EDC) software for clinical trials. This latest production release adds a host of new capabilities designed to further accelerate the adoption of open source into mainstream research.
“We have added powerful new capabilities and made them accessible through an intelligent, task-oriented user interface," said Cal Collins, CEO of Akaza Research.
Key features of OpenClinica 3.0 include: streamlined user interface that simplifies site usage, study progress dashboard, improved query workflows, with notifications, chain of custody, and task management, source data verification workspace, faster page load time, dedicated Study Build module, improved control over significant digits in eCRF data items, job scheduler and web services interface to allow for programmatic data interchange with other systems
As open source software, OpenClinica is free for organizations to use and modify. The software may be downloaded here. Akaza Research will be conducting a webinar presentation of OpenClinica 3.0 on October 28, 2009 to demonstrate the new product and answer questions form the community, click here for information.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
